Sun Pharma launches COVID-19 drug Favipiravir at ₹35 per tablet for treatment of mild cases

August 4: Sun Pharmaceutical Industries on Tuesday launched Favipiravir (200 mg) in India under the brand FluGuard at an economical price of ₹35 per tablet for the treatment of mild to moderate cases of COVID-19. Favipiravir is the only oral anti-viral treatment approved in the country for the potential treatment of patients with mild to moderate COVID-19 disease. Sun Pharma is the world’s fourth-largest specialty generic pharmaceutical company and India’s top pharmaceutical company.

On Tuesday, Kirti Ganorkar, CEO of India Business at Sun Pharma said, “We are launching FluGuard at an economical price to make the drug accessible to more and more patients, thereby reducing their financial burden. This is in line with our continuous efforts to support India”s pandemic response.” The stocks of FluGuard will be available in the market from this week.

The company will work closely with the government and medical community to ensure availability of FluGuard (Favipiravir 200 mg) to patients across the country. The stocks of FluGuard will be available in the market from this week, Sun Pharma said.